The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis

Cancer Research

Volumn 66, Issue 10, 2006, Pages 5330-5337

  Barsyte Lovejoy, Dalia ^a   Lau, Suzanne K ^a,b   Boutros, Paul C ^a,b   Khosravi, Fereshteh ^a   Jurisica, Igor ^a,b,c   Andrulis, Irene L ^d   Tsao, Ming S ^a,b   Penn, Linda Z ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; RNA H19; SOMATOMEDIN;

ACETYLATION; ALLELE; ARTICLE; BREAST CARCINOMA; CARCINOGENESIS; CHROMATIN IMMUNOPRECIPITATION; DOWN REGULATION; FIBROBLAST; GENE CONTROL; GENE LOCUS; GENE SILENCING; GENETIC TRANSCRIPTION; GENOME IMPRINTING; GLIOBLASTOMA; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION;

ACETYLATION; ALLELES; ANIMALS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; GENOMIC IMPRINTING; GLIOBLASTOMA; HISTONES; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LUNG NEOPLASMS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-MYC; RATS; RNA, MESSENGER; RNA, UNTRANSLATED; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 33744912772     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0037     Document Type: Article

References (50)

1. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999;18: 3004-16.
2. Oster SK, Ho CS, Soucie EL, et al. The myc oncogene: MarvelouslY Complex. Adv Cancer Res 2002;84:81-154.
3. McMahon SB, Van Buskirk HA, Dugan KA, et al. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell 1998;94:363-74.
4. Cheng SW, Davies KP, Yung E, et al. c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat Genet 1999;22:102-5.
5. Eberhardy SR, Farnham PJ. Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter. J Biol Chem 2002;277:40156-62.
6. Barsyte-Lovejoy D, Mao DY, Penn LZ. c-Myc represses the proximal promoters of GADD45a and GADD153 by a post-RNA polymerase II recruitment mechanism. Oncogene 2004;23:3481-6.
7. Mao DY, Barsyte-Lovejoy D, Ho CS, et al. Promoter-binding and repression of PDGFRB by c-Myc are separable activities. Nucleic Acids Res 2004;32:3462-8.
8. INK4b expression by Myc through association with Miz-1. Nat Cell Biol 2001;3:392-9.
9. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999;19:1-11.
10. O'Connell BC, Cheung AF, Simkevich CP, et al. A large scale genetic analysis of c-Myc-regulated gene expression patterns. J Biol Chem 2003;278:12563-73.
11. Watson JD, Oster SK, Shago M, et al. Identifying genes regulated in a Myc-dependent manner. J Biol Chem 2002;277:36921-30.
12. Orian A, van Steensel B, Delrow J, et al. Genomic binding by the Drosophila Myc, Max, Mad/Mnt transcription factor network Genes Dev 2003;17:1101-14.
13. Mao DY, Watson JD, Yan PS, et al. Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression. Curr Biol 2003;13:882-6.
14. Li Z, Van Calcar S, Qu C, et al. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A 2003;100:8164-9.
15. Fernandez PC, Frank SR, Wang L, et al. Genomic targets of the human c-Myc protein. Genes Dev 2003;17:1115-29.
16. Cawley S, Bekiranov S, Ng HH, et al. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 2004;116:499-509.
17. Costa FF. Non-coding RNAs: new players in eukaryotic biology. Gene 2005;357:83-94.
18. Hao Y, Crenshaw T, Moulton T, et al. Tumour-suppressor activity of H19 RNA. Nature 1993;365:764-7.
19. Isfort RJ, Cody DB, Kerckaert GA, et al. Role of the H19 gene in Syrian hamster embryo cell tumorigenicity. Mol Carcinog 1997;20:189-93.
20. Adriaenssens E, Dumont L, Lottin S, et al. H19 overexpression in breast adenocarcinoma stromal cells is associated with tumor values and steroid receptor status but independent of p53 and Ki-67 expression. Am J Pathol 1998;153:1597-607.
21. Tanos V, Ariel I, Prus D, et al. H19 and IGF2 gene expression in human normal, hyperplastic, and malignant endometrium. Int J Gynecol Cancer 2004;14:521-5.
22. Kondo M, Suzuki H, Ueda R, et al. Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. Oncogene 1995;10:1193-8.
23. Douc-Rasy S, Barrois M, Fogel S, et al. High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. Uncoupling of H19 and IGF2 expression and biallelic hypomethylation of H19. Oncogene 1996;12:423-30.
24. Hibi K, Nakamura H, Hirai A, et al. Loss of H19 imprinting in esophageal cancer. Cancer Res 1996;56:480-2.
25. Ariel I, Sughayer M, Fellig Y, et al. The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. Mol Pathol 2000;53:320-3.
26. Reik W, Walter J. Genomic imprinting: parental influence on the genome. Nat Rev Genet 2001;2:21-32.
27. Macleod D, Ali RR, Bird A. An alternative promoter in the mouse major histocompatibility complex class III-Abeta gene: implications for the origin of CpG islands. Mol Cell Biol 1998;18:4433-43.
28. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003;30:256-68.
29. Oster SK, Mao DY, Kennedy J, et al. Functional analysis of the N-terminal domain of the Myc oncoprotein. Oncogene 2003;22:1998-2010.
30. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
31. Andrulis IL, Bull SB, Blackstein ME, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 1998;16:1340-9.
32. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002;30:e15.
33. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology 2003;3:1-26.
34. Paddison PJ, Caudy AA, Bernstein E, et al. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002;16:948-58.
35. Berteaux N, Lottin S, Monte D, et al. H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1. J Biol Chem 2005;280:29625-36.
36. Prendergast GC, Ziff EB. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science 1991;251:186-9.
37. Perini G, Diolaiti D, Porro A, et al. In vivo transcriptional regulation of N-Myc target genes is controlled by E-box methylation. Proc Natl Acad Sci U S A 2005;102:12117-22.
38. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
39. Yan H, Yuan W, Velculescu VE, et al. Allelic variation in human gene expression. Science 2002;297:1143.
40. Bachman KE, Park BH, Rhee I, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 2003;3:89-95.
41. Wilkin F, Paquette J, Ledru E, et al. H19 sense and antisense transgenes modify insulin-like growth factor-II mRNA levels. Eur J Biochem 2000;267:4020-7.
42. Raetz EA, Kim MK, Moos P, et al. Identification of genes that are regulated transcriptionally by Myc in childhood tumors. Cancer 2003;98:841-53.
43. Kaneda A, Feinberg AP. Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res 2005;65:11236-40.
44. Brannan CI, Dees EC, Ingram RS, et al. The product of the H19 gene may function as an RNA. Mol Cell Biol 1990;10:28-36.
45. Lottin S, Adriaenssens E, Dupressoir T, et al. Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. Carcinogenesis 2002;23:1885-95.
46. Ayesh S, Matouk I, Schneider T, et al. Possible physiological role of H19 RNA. Mol Carcinog 2002;35:63-74.
47. Jones BK, Levorse JM, Tilghman SM. Igf2 imprinting does not require its own DNA methylation or H19 RNA. Genes Dev 1998;12:2200-7.
48. Li YM, Franklin G, Cui HM, et al. The H19 transcript is associated with polysomes and may regulate IGF2 expression in trans. J Biol Chem 1998;273:28247-52.
49. Lottin S, Vercoutter-Edouart AS, Adriaenssens E, et al. Thioredoxin post-transcriptional regulation by H19 provides a new function to mRNA-like non-coding RNA. Oncogene 2002;21:1625-31.
50. Weinmann AS, Yan PS, Oberley MJ, et al. Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis. Genes Dev 2002;16:235-44.